Milestone payment for ALK following new Japanese study
The Japanese partner of Danish company ALK-Abello has started new, late-stage clinical trials with the allergy company’s innovative hay fever and asthma pill. It triggers a milestone payment for the Danish company.
Two newly initiated phase 2/3 studies will spell extra profit for ALK-Abello. The Danish pharmaceutical group’s Japanese partner has begun concluding clinical trials with the pill Mitizax against hay fever and asthma caused by house dust mites.